Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 37

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 37
---
 or products commercially in the U.S., Europe and elsewhere. Now, and in the future, an individual may bring a liability claim against SKNY alleging that one of its product candidates caused an injury. While SKNY continues to take what it believes are appropriate precautions, it may be unable to avoid significant liability if any product liability lawsuit is brought against it. Large judgments have been awarded in class action or individual lawsuits based on drugs that had unanticipated side effects. If SKNY cannot successfully defend itself against product liability claims, it will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:

| ● | decreased                                                                   
 demand for SKNY product candidates if such product candidates are approved; |

| 18 |

| ● | injury to our reputation;                                 |
| ● | withdrawal of clinical trial participants;                |
| ● | costs of related litigation;                              |
| ● | substantial monetary awards to patients and others;       |
| ● | increased cost of liability insurance;                    |
| ● | loss of revenue; and                                      |
| ● | the inability to successfully commercialize our products. |

SKNY depends upon its key personnel and ability to attract and retain employees.

SKNY’s future growth and success depend on its ability to recruit, retain, manage, and motivate employees. The inability to hire or retain experienced management personnel could adversely affect SKNY’s ability to execute its business plan and harm its operating results. Due to the specialized scientific and managerial nature of SKNY’s business, it relies heavily on its ability to attract and retain qualified scientific, technical, and managerial personnel. The competition for qualified personnel in the pharmaceutical field is intense. Due to this intense competition, SKNY may be unable to attract and retain the qualified personnel necessary for the development of its business or to recruit suitable replacement personnel.

SKNY is subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing its operations. If SKNY fails to comply with these laws, it could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect its business, results of operations and financial condition.

SKNY’s operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”), and other anti-corruption laws that apply in countries where it does business. The FCPA and these other laws generally prohibit SKNY’s